Simplified 10-Year Absolute Fracture Risk Assessment: A Comparison of Men and Women
Abstract
A simplified (semiquantitative) approach developed by the Canadian Association of Radiologists and Osteoporosis Canada (denoted as CAROC) for absolute fracture risk assessment incorporates age, sex, prior fragility fracture, and systemic corticosteroid use, together with bone mineral density (BMD) to define absolute fracture risk. The CAROC system has been shown to predict fracture rates in women referred for clinical BMD testing, but it is uncertain how this system performs in routine clinical practice in men who are much less likely to undergo BMD testing with potential for referral biases. Thirty-six thousand seven hundred and thirty women and 2873 men aged 50
yr or older at the time of baseline BMD testing were identified in a database containing all clinical dual-energy X-ray absorptiometry test results for the Province of Manitoba, Canada. Population-based health service records from 1987 to 2008 were assessed for fracture codes and medication use. Fracture risk under the CAROC model was categorized as low (<10%), moderate (10–20%), or high (>20%). Ten-year fracture risk estimated by the Kaplan-Meier method showed the same gradient in observed fracture risk for men and women. Despite evidence of greater referral bias in men resulting in a higher rate of clinical risk factors, the performance of the prediction algorithm was not affected.
Key Words: Absolute risk, administrative data, bone mineral density, dual-energy X-ray absorptiometry, fractures, historical cohort study, men, osteoporosis
To access this article, please choose from the options below
Disclosures—William D. Leslie: In the past 3
yr, W.D.L. has received speaker fees from Merck Frosst Canada Ltd. and unrestricted research grants from Merck Frosst Canada Ltd; Sanofi-Aventis; Procter & Gamble Pharmaceuticals Canada, Inc.; Novartis; Amgen Pharmaceuticals Canada, Inc.; innovus 3M; and Genzyme Canada. He has served on advisory boards for Genzyme Canada; Novartis; and Amgen Pharmaceuticals Canada, Inc. Lisa M. Lix: In the past 3
yr, L.M.L. has received unrestricted research grants from Amgen Pharmaceuticals Canada, Inc., and innovus 3M.
Sources of support: None.
PII: S1094-6950(10)00147-2
doi:10.1016/j.jocd.2010.02.002
© 2010 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.
